Cargando…
Role of Tegoprazan in Helicobacter pylori Eradication Therapy
Autor principal: | Lee, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of Gut and Liver
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289832/ https://www.ncbi.nlm.nih.gov/pubmed/35843681 http://dx.doi.org/10.5009/gnl220272 |
Ejemplares similares
-
Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
por: Park, Chan Hyuk, et al.
Publicado: (2022) -
Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication
por: Kwon, Yong Hwan, et al.
Publicado: (2023) -
Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study
por: Jung, Yoon Suk, et al.
Publicado: (2023) -
Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori
por: Lee, Jung Won, et al.
Publicado: (2021) -
Recent advances in Helicobacter pylori eradication
por: Niv, Yaron, et al.
Publicado: (2015)